La stimolazione atriale transesofagea nel trattamento orale della tachicardia parossistica reciprocante sopraventricolare del lattante

Translated title of the contribution: Usefulness of transesophageal atrial pacing in the chronic treatments of supraventricular reciprocating tachycardia in infants

F. Drago, A. Turchetta, P. Guccione, A. Santilli, E. Pompei, M. G. Gagliardi, A. Calzolari, P. Ragonese

Research output: Contribution to journalArticle

Abstract

Introduction. The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home. Methods. We studied 13 infants (11 males, 2 females, mean age 43 ± 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 5 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out. Results. The number of oral treatments tested for each patient were 2 ± 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 ± 2 (range 3-7). No patient had symptomatic episodes of supraventrioular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences. Conclusion. Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protodcol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.

Original languageItalian
Pages (from-to)11-16
Number of pages6
JournalGiornale Italiano di Cardiologia
Volume25
Issue number1
Publication statusPublished - 1995

Fingerprint

Reciprocating Tachycardia
Supraventricular Tachycardia
Therapeutics
Tachycardia
Recurrence
Heart Diseases
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

La stimolazione atriale transesofagea nel trattamento orale della tachicardia parossistica reciprocante sopraventricolare del lattante. / Drago, F.; Turchetta, A.; Guccione, P.; Santilli, A.; Pompei, E.; Gagliardi, M. G.; Calzolari, A.; Ragonese, P.

In: Giornale Italiano di Cardiologia, Vol. 25, No. 1, 1995, p. 11-16.

Research output: Contribution to journalArticle

@article{e9c2a7fe14e64dde842689d7eac71fc8,
title = "La stimolazione atriale transesofagea nel trattamento orale della tachicardia parossistica reciprocante sopraventricolare del lattante",
abstract = "Introduction. The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home. Methods. We studied 13 infants (11 males, 2 females, mean age 43 ± 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 5 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out. Results. The number of oral treatments tested for each patient were 2 ± 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 ± 2 (range 3-7). No patient had symptomatic episodes of supraventrioular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences. Conclusion. Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protodcol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.",
keywords = "infant, supraventricular tachycardia",
author = "F. Drago and A. Turchetta and P. Guccione and A. Santilli and E. Pompei and Gagliardi, {M. G.} and A. Calzolari and P. Ragonese",
year = "1995",
language = "Italian",
volume = "25",
pages = "11--16",
journal = "Giornale Italiano di Cardiologia",
issn = "0046-5968",
publisher = "Societa Italiana di Cardiologia",
number = "1",

}

TY - JOUR

T1 - La stimolazione atriale transesofagea nel trattamento orale della tachicardia parossistica reciprocante sopraventricolare del lattante

AU - Drago, F.

AU - Turchetta, A.

AU - Guccione, P.

AU - Santilli, A.

AU - Pompei, E.

AU - Gagliardi, M. G.

AU - Calzolari, A.

AU - Ragonese, P.

PY - 1995

Y1 - 1995

N2 - Introduction. The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home. Methods. We studied 13 infants (11 males, 2 females, mean age 43 ± 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 5 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out. Results. The number of oral treatments tested for each patient were 2 ± 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 ± 2 (range 3-7). No patient had symptomatic episodes of supraventrioular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences. Conclusion. Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protodcol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.

AB - Introduction. The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home. Methods. We studied 13 infants (11 males, 2 females, mean age 43 ± 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 5 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out. Results. The number of oral treatments tested for each patient were 2 ± 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 ± 2 (range 3-7). No patient had symptomatic episodes of supraventrioular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences. Conclusion. Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protodcol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.

KW - infant

KW - supraventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=0029434189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029434189&partnerID=8YFLogxK

M3 - Articolo

C2 - 7642007

AN - SCOPUS:0029434189

VL - 25

SP - 11

EP - 16

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 0046-5968

IS - 1

ER -